Journey Medical (NASDAQ:DERM) Announces Quarterly Earnings Results

Journey Medical (NASDAQ:DERM) issued its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03), FiscalAI reports. The business had revenue of $18.97 million for the quarter, compared to analyst estimates of $20.32 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.

Here are the key takeaways from Journey Medical’s conference call:

• Emrosi continued to gain traction: The company reported $9 million in third-quarter net sales, about 40,000 prescriptions and more than 5,000 unique prescribers. Prescriptions grew sequentially, supported by strong refills and a growing prescriber base.
• Profitability improved: Journey Medical reported positive EBITDA for a second consecutive quarter, and its GAAP net loss narrowed to $1.3 million from $3.9 million a year earlier. Adjusted EBITDA was $3.5 million.
• Payer coverage could support future revenue per prescription: About 40% of commercial lives currently have what the company calls high-quality coverage. A national plan covering more than 25 million lives is expected to add Emrosi to its formulary in January 2027, though management said deductible resets may delay the benefit and offered no formal 2027 guidance.
• Near-term prescription trends have been volatile: Management attributed a recent dip to raising the copay in its bridging program from $0.35 to $0.50 and said recovery may take four to eight weeks. It expects Q4 to approach break-even before prescriptions begin to rise again.
• Costs and cash remain considerations: SG&A included a one-time $1.7 million cash payment to settle a former vendor dispute. Cash was $22.3 million at quarter-end, down from $24.1 million at the end of 2025, and management is considering further investment in Emrosi sales and market-access efforts.

Journey Medical Stock Performance

Shares of NASDAQ:DERM traded down $0.08 on Friday, hitting $4.31. 85,290 shares of the company were exchanged, compared to its average volume of 212,278. The firm has a market capitalization of $121.57 million, a P/E ratio of -19.47 and a beta of 1.14. The company has a current ratio of 1.59, a quick ratio of 1.41 and a debt-to-equity ratio of 0.64. Journey Medical has a 1-year low of $4.00 and a 1-year high of $9.56. The stock’s 50 day moving average price is $5.96 and its 200 day moving average price is $6.49.

Journey Medical News Summary

Investors following DERM have been watching these news items:

• Positive Sentiment: Journey Medical’s third-quarter loss narrowed year over year and revenue rose; shares gained after hours following the results. Journey Medical Q3 Loss Narrows, Revenue Rises; Shares Gain After Hours
• Neutral Sentiment: B. Riley reaffirmed its “buy” rating but lowered its price target to $13 from $15, reflecting a more cautious outlook despite substantial potential upside from the reported share price. B. Riley rating and price target update
• Negative Sentiment: Quarterly EPS was a loss of $0.05, worse than the expected $0.02 loss. Revenue of $18.97 million also missed the $20.32 million consensus estimate, highlighting ongoing pressure on performance. Journey Medical Q3 earnings results

Analysts Set New Price Targets

A number of analysts have recently weighed in on DERM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research report on Thursday, October 15th. B. Riley Financial restated a “buy” rating and set a $13.00 target price (down from $15.00) on shares of Journey Medical in a research note on Friday. Wall Street Zen lowered Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Journey Medical in a research report on Monday, October 26th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $13.00.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.